Sonoma Pharmaceuticals, Inc. 8-K

What Happened

• Sonoma Pharmaceuticals, Inc. (SNOA) filed a Form 8-K on January 12, 2026 (Item 8.01) to attach an updated investor presentation, which is filed as Exhibit 99.1. The presentation includes forward-looking statements about the company’s commercial and technology progress and future financial performance under the Private Securities Litigation Reform Act “safe harbor.” The filing does not report earnings or other financial results.

Key Details

• Filing date: January 12, 2026 (Form 8-K, Item 8.01).
• Exhibit: Updated investor presentation submitted as Exhibit 99.1.
• Forward-looking statements: Identified by words such as “will,” “expect,” and “project”; company disclaims obligation to update these except as required by law.
• Risks noted in the presentation include regulatory/clinical developments, patent protection challenges, market size and product penetration, revenue sufficiency, and currency/trade policy uncertainties.

Why It Matters

• The updated investor presentation is the company’s current public overview of strategy, commercial and technology progress, and expectations—useful for investors tracking SNOA’s milestones and outlook. Because the material contains forward-looking statements and a list of risks, investors should review the presentation alongside Sonoma’s prior SEC filings to understand the assumptions and potential risks underlying the company’s projections.